- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00969696
Galantamine Effects on Cognitive Function in Marijuana Users
Study Overview
Detailed Description
To summarize, marijuana users show impaired cognitive functioning, especially in working memory and verbal learning and memory functions. Impaired cognitive functioning predicts poor treatment response in marijuana users. Whether the cognitive impairments in marijuana users improve with cholinergic enhancers has not been evaluated. In this double-blind, parallel-group study, we are proposing to evaluate galantamine's effects on cognitive performance in marijuana users. Thirty subjects will first have an adaptation session to familiarize them with the study procedures including cognitive assessment. The adaptation session will be followed by a 10-day treatment period, in which subjects will be randomized to galantamine (8 mg/day) or placebo. On Day 4 or 5 and Day 9 or10 of each treatment phase subjects will have test sessions, where a battery of cognitive tests will be administered. The cognitive test that will be administered will include the Hopkins Verbal Learning Test (HVLT) modules from the Cambridge Neuropsychological Test Automated Battery (CANTAB): the Rapid Visual Information Processing (RVIP) and the Stop Signal Test (SST).
Currently this study is in data analysis with 30 completers. (April 2011)
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Connecticut
-
West Haven, Connecticut, United States, 06516
- Department of Veterans Affairs
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women between the ages of 18 and 55 who are dependent on or abuse marijuana, according to DSM-IV criteria;
- History of marijuana use on the average of at least twice a week over a one-month period;
- Current marijuana use, indicated by positive urine toxicology for marijuana;
- No current medical problems and normal ECG;
- For women, neither pregnant as determined by pregnancy screening nor breast feeding, and using acceptable birth control methods.
Exclusion Criteria:
- Current major psychiatric illnesses including mood, psychotic, or anxiety disorders;
- Current dependence to other drugs of abuse or alcohol (except nicotine or marijuana dependence);
- History of major medical illnesses including asthma or chronic obstructive lung disease, history or current gastrointestinal ulcer, hepatic or renal impairment and cardiac rhythm disturbances or other medical conditions that the study physician deems contraindicated for the subject to be in the study;
- Use of other medications including a) drugs that slow heart rate (eg, beta-blockers),which may increase the risk of bradycardia and AV block and b) NSAIDs; increased potential for developing ulcers/active or occult gastrointestinal bleeding;
- Known allergy to galantamine
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Galatamine
Galantamine is used for the treatment of mild to moderate Alzheimer's disease and various other memory
|
8mg of Galantamine
|
Placebo Comparator: Sugar Pill
|
8Mg a day of a sugar pill
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
test whether galantamine in comparison to placebo, will improve cognitive functioning and the effects of galantamine on mood.
Time Frame: two years
|
two years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mehmet Sofuoglu, M.D., Ph.D., Yale University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- Marijuana Abuse
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Agents
- Enzyme Inhibitors
- Nootropic Agents
- Cholinesterase Inhibitors
- Parasympathomimetics
- Galantamine
Other Study ID Numbers
- 0905005104
- P50DA009241 (U.S. NIH Grant/Contract)
- MIREC (Registry Identifier: Veteran's Administration)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Memory
-
Kutahya Health Sciences UniversityCompletedWorking Memory | The Working Memory QuestionnaireTurkey
-
Prof. Dominique de Quervain, MDClinical Trial Unit, University Hospital Basel, SwitzerlandCompletedMemory, Short-Term | Memory, Long-TermSwitzerland
-
Memorial Sloan Kettering Cancer CenterCompletedMemory Losses | Amnesia-Memory LossUnited States
-
University of Electronic Science and Technology...CompletedOxytocin Effect on Memory Performance During Phase 1 | Oxytocin Effect on Memory Performance During Phase 2 | Oxytocin Effect on Memory Performance During Phase 3 | Oxytocin Effect on Memory Performance During Phase 4China
-
University of Maryland, College ParkUniversity of Massachusetts, AmherstRecruiting
-
Prof. Dominique de Quervain, MDNot yet recruiting
-
University of PennsylvaniaRecruiting
-
University of BaselTerminated
-
Colorado State UniversityInstitute of Cannabis ResearchCompleted
-
University Hospital, GrenobleTIMC-IMAGUnknown
Clinical Trials on Galantamine
-
Yale UniversityNational Institute on Drug Abuse (NIDA)Completed
-
Samsung Medical CenterJanssen Korea, Ltd., KoreaCompleted
-
Ludwig-Maximilians - University of MunichUnknownAlzheimer's DiseaseGermany
-
Icahn School of Medicine at Mount SinaiNational Institute of Mental Health (NIMH); Massachusetts General HospitalCompletedBipolar DisorderUnited States
-
The University of Texas Health Science Center,...Completed
-
Janssen Pharmaceutical K.K.CompletedAlzheimer's DiseaseJapan
-
Actavis Inc.Completed
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedAlzheimer Disease
-
Actavis Inc.Completed